Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Partners Indian Research Agency For ‘Malaria-Free’ Initiative

This article was originally published in PharmAsia News

Executive Summary

India's biggest drug firm, Sun Pharma, has teamed up with the Indian Council of Medical Research in a public-private partnership to create a malaria-free India. But the initiative comes as scientists worry that a powerful new drug-resistant strain of the disease could be about to emerge in the country.

You may also be interested in...



Sun Evaluating Plant-Based Candidates To Treat Zika

Sun Pharma expects to study plant-based drug candidates to treat the Zika virus in a tie-up with India’s state-run National Institute of Virology, as part of a wider initiative to test new medicines to act against mosquito-borne diseases.

Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine

Europe’s CHMP grants positive opinions for Sanofi’s Praluent and GSK’s not-for-profit malaria vaccine Mosquirix at July meeting; other products recommended include Shire’s Intuniv, Merck’s Zerbaxa, Basilea’s Cresemba and Keryx’s Fexeric.

Share Fillip As Indian Pharma Crests US Regulatory Hump

For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC089550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel